大笑い(笑) 0604山師さん@トレード中 (ワッチョイ 238e-tRsh [202.124.52.145 [上級国民]])2018/08/08(水) 23:02:01.97ID:DlgxTxbd0 Pluristem: ・・・ ※Pluristem 2Q Report: "Our Expectations; Sosei CVC"; "Pluristem is working hard to negotiate the best possible terms for a Japanese JV and will provide an update upon reaching an agreement." (2/7) ※Pluristem 3Q Report: "The proposed joint venture, with Sosei CVC for the clinical development and commercialization in Japan, the plan to enter into definitive agreements and the timing of entering into such agreements." (5/9) ※Pluristem: Announced that the top-line results of the company’s multinational Phase II clinical trial of PLX-PAD cells in the treatment of Intermittent Claudication (IC) will be released on June 12, 2018. (6/4) ※Pluristem Reports: Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study: PLX-PAD treatment reduced risk of revascularization and improved patients’ mobility. (6/12) ※Pluristem: "These study results are highly encouraging and suggest that PLX-PAD cells may be the answer for both PAD patients and physicians seeking effective medical solutions". (6/12) ※Reuters: Israel's Pluristem sees positive results from leg pain study: The study’s results also validate the design of Pluralism’s advanced Phase III trial for CLI, the company said. (6/12) ※Pluristem: Pluristem to Open Weekly Market Trading at TASE Following Positive Study Results. (6/14) ※Pluristem: U.S. Department of Defense to Study Pluristem’s PLX-R18 for the Treatment of Mustard Gas Injuries Studies to be funded by the U.S. NIH Marks the second project for DOD with PLX-R18 cell therapy product. (6/19) ※Seeking Alpha: Pluristem's PLX-PAD Cell Therapy Promising As A Non-Invasive Treatment For Peripheral Artery Disease. (6/19) ※Pluristem: and Fukushima University Report Positive Data: PLX-R18 Increases Survival Rates and Mitigates Severe Intestinal Damage after Acute Radiation Exposure. (6/25) ※Pluristem: A Glimpse from the Media: Study shows placenta treatment effective against radiation sickness. Pluristem has been working with researchers in Fukushima, the site of nuclear meltdowns in 2011, to treat acute radiation syndrome. (6/27up) ※World Congress of Basic and Clinical Pharmacology, Kyoto: "PLX-R18- Placenta-derived Mesenchymal-like Stromal Cells are efficacious in reducing lethality in Gastrointestinal Acute Radiation Syndrome (GI-ARS) Mouse Model": Yoshiyuki Soeda, Fukushima Medical University. (7/3 Presented) ※Pluristem: Signs Collaboration Agreement With Thermo Fisher Scientific: Advance fundamental knowledge of cell therapy industrialization and to improve quality control of the end-to-end supply chain. "A potential to advance the industry significantly". (7/9) ※Pluristem: Company Presentation July 2018. Critical Limb Ischemia (CLI): PLX-PAD: Single pivotal study (Japan). Collaboration with Fukushima Medical University: Evaluating PLX-R18 cells as a treatment for radiation damage to the gastrointestinal (GI) tract and bone marrow. (7/23update) ※Pluristem: "New patent in Japan- covers PLX-R18’s protection of the gastrointestinal (GI) tract from radiation exposure". Recent data from Fukushima University shows PLX-R18 cells significantly increased survival and enhanced the recovery of the GI tract after radiation exposure (7/26) ↓ 0605山師さん@トレード中 (ワッチョイ 238e-tRsh [202.124.52.145 [上級国民]])2018/08/08(水) 23:02:22.96ID:DlgxTxbd0 ※Pluristem 2時間前:Pluristem Initiates Two Pivotal Phase III Studies in several clinical sites in Israel. (8/8) ※Pluristem Initiates Two Pivotal Phase III Studies in Israel. (8/8) “Numerous Clinical Sites in Israel to join sites in the U.S. and Europe for Pivotal Phase III Studies of PLX-PAD Cell Therapy in the Treatment of Critical Limb Ischemia and Muscle Injury Following Hip Fracture” HAIFA, Israel, Aug. 08, 2018 - Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced today that Israel’s Ministry of Health has cleared the Company to commence patient recruitment in Israel for two ongoing pivotal Phase III trials of PLX-PAD cell therapy, one for the treatment of Critical Limb Ischemia (CLI) and another for the treatment of muscle injury following hip fracture surgery. Both trials have been accepted to accelerated approval pathways and have received a total of $16.7 million in grants from the European Union’s Horizon 2020 Program. “We are pleased to open clinical sites in Israel for both of our ongoing pivotal Phase III studies. These sites may enable Pluristem to apply for marketing approval in Israel for both indications, aligning with potential regulatory approvals in the U.S. and Europe and expedite the completion of recruitment of both pivotal trials,” stated Pluristem Chairman and Co-CEO, Zami Aberman. Pluristem’s pivotal Phase III study of PLX-PAD cells in the treatment of CLI, which has received an $8 million grant from the European Union’s Horizon 2020 program, and is currently recruiting patients in the U.S., U.K., Germany, Poland, Czech Republic, Hungary, Bulgaria and Macedonia. PLX-PAD has received the U.S. Food and Drug Administration’s (FDA) Fast Track designation for the treatment of CLI and has been included in the European Medicines Agency (EMA) Adaptive Pathways program, which may lead to early conditional marketing authorization based on an interim analysis following treatment of half of the total 246 patients to be enrolled in the study. The FDA recently cleared PLX-PAD for its Expanded Access Program (EAP) for the treatment of patients with CLI who are not eligible for Pluristem’s Phase III study. EAP allows the use of an investigational medical product outside of clinical trials and is usually granted in cases where patients are unsuitable for inclusion under the study protocol and the patient’s condition is life-threatening with an unmet medical need. Pluristem’s pivotal Phase III study in the treatment of muscle injury following arthroplasty for hip fracture was awarded an $8.7 million grant by the European Horizon 2020 Program. This study will recruit 240 patients through clinical sites in the U.S., Europe and Israel. 0606山師さん@トレード中 (ワッチョイ ef23-0Uuo [111.99.103.209])2018/08/08(水) 23:05:05.77ID:r8ri6pTa0 決算発表明日か。 0607山師さん@トレード中 (スップ Sd5f-Bh6x [1.66.104.254])2018/08/08(水) 23:17:47.77ID:fDaowFZAd 30億赤字だと思っとけばok? 0608山師さん@トレード中 (オイコラミネオ MM93-IOKZ [150.66.103.25])2018/08/09(木) 06:47:27.95ID:b+tj+VxVM 役員報酬ガバガバなのに赤字が少ないならサプライズすぎるわ 0609山師さん@トレード中 (ワッチョイW e34b-RFoT [182.166.18.119])2018/08/09(木) 07:35:38.03ID:tyEtI0L60 常軌を逸した粘着ぶり、底辺に嫉妬されると怖いなぁ ネットに書くのは構わんけど人殺すなよマジで 0610山師さん@トレード中 (オッペケ Sreb-FkxC [126.237.117.212])2018/08/09(木) 07:49:14.45ID:vXDuYf6Mr 今日も右肩下がりの安値引けで、35億の赤字出して明日は暴落か…トホホ… 0611山師さん@トレード中 (ワッチョイW 676d-g1QT [218.228.130.47])2018/08/09(木) 07:53:11.53ID:Lg66jOnI0>>610 空売り機関の筋書き通り 決算後3桁 0612山師さん@トレード中 (ワッチョイWW c76d-+svk [112.70.53.84])2018/08/09(木) 08:03:51.63ID:ORDx46II0>>610 35で済んだらいいけどな‥ 0613山師さん@トレード中 (アウアウカー Sa73-g1QT [182.251.242.39])2018/08/09(木) 08:11:50.13ID:whZ2H1Txa 気配大暴落w 0614山師さん@トレード中 (オッペケ Sreb-FkxC [126.237.117.212])2018/08/09(木) 08:12:06.47ID:vXDuYf6Mr>>612 40億もあるってこと?まじかよそりゃ暴落するよね…トホホ… 0615山師さん@トレード中 (ワッチョイ 536f-5RUY [60.42.240.174])2018/08/09(木) 08:16:01.77ID:xNG72IcL0 激しくどーーーん。 0616山師さん@トレード中 (アウアウカー Sa73-g1QT [182.251.242.39])2018/08/09(木) 08:16:59.02ID:whZ2H1Txa 空売り機関ロックオン! とりあえずのターゲットは2桁 0617山師さん@トレード中2018/08/09(木) 08:35:03.62ID:1sYUGyHI>>613 おい、画像うpまだか?